DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 086413
describes TRIAMCINOLONE ACETONIDE
, which is a drug marketed by Mylan Pharms Inc, Taro, Parnell, Perrigo Israel, Teligent Pharma Inc, Pharmafair, Akorn, Perrigo New York, Alpharma Us Pharms, Glenmark Pharms Ltd, Watson Labs, G And W Labs Inc, Ambix, Wockhardt Eu Operatn, Wockhardt, Lupin Atlantis, Sandoz Inc, Fougera Pharms, Vintage, Lyne, Topiderm, Perrigo Uk Finco, Pharmaderm, Morton Grove, G And W Labs, Actavis Mid Atlantic, and Cmp Pharma Inc, and is included in seventy-three NDAs. It is available from fifty-six suppliers. Additional details are available on the TRIAMCINOLONE ACETONIDE profile page.
The generic ingredient in TRIAMCINOLONE ACETONIDE is triamcinolone acetonide. There are fifty drug master file entries for this compound. Eighty-two suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
Complete Access Available with Subscription
Summary for product number 001
|Approval Date:||Approved Prior to Jan 1, 1982||TE:||AT||RLD:||No|
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.